🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

12 recruiting trials

for Pulmonary Large-cell Neuroendocrine Carcinoma

FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum NCT06393816Phase 231 sites📍 Aix-en-Provence📍 Amiens📍 Angers Centre Leon Berard · Tests: Durvalumab with etoposide and Carboplatin/Cisplatin Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors NCT07006727Phase 18 sites📍 Iowa City📍 Boston📍 Royal Oak Novartis Pharmaceuticals · Tests: 225Ac-ETN029, 111In-ETN029 Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors NCT07278479Phase 1, Phase 28 sites📍 Tampa📍 Atlanta📍 Chicago Molecular Partners AG · Tests: [212Pb]Pb-MP0712, [203Pb]Pb-MP0712 A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) NCT05652686Phase 1, Phase 215 sites📍 Duarte📍 Los Angeles📍 Denver Phanes Therapeutics · Tests: Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel., Atezolizumab, Lurbinectedin Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors NCT07410494Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors NCT06814496Phase 1, Phase 23 sites📍 Gilbert📍 Tucson📍 Seattle University of Arizona · Tests: Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs) NCT06937905Phase 340 sites📍 Angers📍 Avignon📍 Besançon Intergroupe Francophone de Cancerologie Thoracique · Tests: Standard of Care Chemotherapy, Tarlatamab Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors NCT07080242Phase 131 sites📍 Huntsville📍 Glendale📍 Long Beach SystImmune Inc. · Tests: BL-M14D1 Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS) NCT06717243n/a2 sites📍 New York📍 Athens Oncology Center of Biochemical Education And Research · Tests: Carboplatin/Cisplatin -Etoposide - Atezolizumab A Study of FZ-AD005 in Patients With Advanced Solid Tumors NCT06424665Phase 13 sites📍 Changsha📍 Shanghai📍 Hangzhou Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Tests: FZ-AD005 Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER) NCT06228066Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: Lurbinectedin, Avelumab Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC) NCT06418087Phase 215 sites📍 Bologna📍 Viagrande📍 Meldola Gruppo Oncologico Italiano di Ricerca Clinica · Tests: Durvalumab 50 MG/1 ML Intravenous Solution [IMFINZI]
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy